Evidence map›Paper›PMID 35820850›Full record

ArticleBMC gastroenterology2022

Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up.

Paul J Clark, Patricia C Valery, James Ward, Simone I Strasser, Martin Weltman, Alexander Thompson, Miriam T Levy, Barbara Leggett, Amany Zekry, Julian Rong and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 20 institutions in 1 country.

Paul J Clark *Department of Gastroenterology, Mater Hospital Brisbane, Raymond Terrace, South Brisbane, QLD, 4101, Australia. paul.j.clark@uq.edu.au.
Patricia C Valery *QIMR Berghofer Medical Research Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-8823-3006
James WardUQ Poche Centre for Indigenous Health, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-2892-4542
Simone I StrasserAW Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-6374-1525
Martin WeltmanHepatology Services, Nepean Hospital, Penrith, NSW, Australia.
Alexander ThompsonDepartment of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia.
Miriam T LevyDepartment of Gastroenterology and Liver, Liverpool Hospital, Sydney, NSW, Australia.
Barbara LeggettDepartment of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Amany ZekryDepartment of Gastroenterology and Hepatology, St George Hospital, Sydney, NSW, Australia.
Julian RongGippsland Gastroenterology, Latrobe Regional Hospital, Traralgon, VIC, 3844, Australia.
Peter AngusDepartment of Gastroenterology and Hepatology, Austin Hospital, Melbourne, VIC, Australia.
Jacob GeorgeStorr Liver Unit, Westmead Hospital, Westmead, NSW, Australia.
Steven BollipoGastroenterology Department, John Hunter Hospital, New Lambton, NSW, Australia.
Bruce McGarityBathurst Liver Clinic Bathurst Hospital, Bathurst, NSW, Australia.
William SievertGastrointestinal and Liver Unit, Monash Health, Melbourne, VIC, Australia.
Gerry MacquillanLiver Transplant Unit Sir Charles Gairdner Hospital, Nedlands Perth, WA, Australia.
Edmund TseHepatology, Royal Adelaide Hospital, Adelaide, SA, Australia.
Amanda NicollEastern Health Box, Hill, VIC, Australia.
Amanda WadeBarwon Health Liver Clinic University Hospital, Geelong, VIC, Australia.
Geoff ChuOrange Liver Clinic, Orange Hospital, Orange, NSW, Australia.
Damian HardingDepartment of Gastroenterology and Hepatology, Lyell McEwin Hospital, Vale, SA, Australia.
Wendy ChengDepartment of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, WA, Australia.
Geoff FarrellGastroenterology and Hepatology Unit Canberra Hospital, Canberra, ACT, Australia.
Stuart K RobertsThe Alfred Hospital, Melbourne, VIC, Australia.
The University of Queensland · AUAustin Hospital · AUBarwon Health · AUCanberra Hospital · AUEastern Health · AUJohn Hunter Hospital · AULatrobe Regional Hospital · AULiverpool Hospital · AULyell McEwin Hospital · AUMater Health Services · AUMonash Health · AUNepean Hospital · AURoyal Adelaide Hospital · AURoyal Brisbane and Women's Hospital · AURoyal Perth Hospital · AUSir Charles Gairdner Hospital · AUSt George Hospital · AUSt Vincent's Hospital Melbourne · AUThe Alfred Hospital · AUThe University of Sydney · AU

Funding

Commonwealth Department of Health (2018-19/05156)
6 · The paper itself

Abstract

backgroundFirst Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection.

methodsAdults who initiated DAA therapy at one of 26 hospitals across Australia, 2016-2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU.

resultsCompared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients; p = 0.51) and 'good' adherence (90.0% vs. 86.9%, respectively; p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87-0.99) and treatment initiation in 2018-2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23-21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50-0.99).

conclusionsOur data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed.

Indexed as

Hepatitis CHepatitis C, ChronicAdultAgedAntiviral AgentsAustraliaFollow-Up StudiesHepacivirusHumansNational Health ProgramsProspective StudiesSustained Virologic ResponseAntiviral AgentsData linkageLiver fibrosisLoss to follow-upSustained viral response

Identifiers

PMID35820850
PMCPMC9275019
OpenAlexW4285025828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.